Targeted approaches to triple-negative breast cancer: current practice and future directions

Area of Science:

• Oncology
• Cancer Research
• Biomarkers

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by negative staining for estrogen receptor (ER), progesterone receptor (PR), and HER2.
• TNBC exhibits a high rate of early relapse and lacks targeted therapies like hormonal therapy or trastuzumab.
• The absence of specific molecular targets necessitates research into novel vulnerabilities and biomarkers for TNBC.

Purpose of the Study:

• To review current research and ongoing clinical trials for novel therapeutic strategies targeting triple-negative breast cancer.
• To highlight the need for identifying new biomarkers and drug targets beyond traditional ER, PR, and HER2 pathways.
• To discuss challenges in TNBC research, such as small sample sizes and retrospective study designs.

Main Methods:

• Review of preclinical and early-phase clinical trials for TNBC treatment.
• Categorization of investigational drugs into four groups: DNA damaging agents, PARP inhibitors, tyrosine-kinase inhibitors/monoclonal antibodies, and downstream signal inhibitors.
• Analysis of current research priorities and challenges in TNBC clinical studies.

Main Results:

• Several novel drug classes are under investigation for TNBC, including DNA damaging agents, PARP inhibitors, and tyrosine-kinase inhibitors.
• Ongoing preclinical and early-phase clinical trials show promise but are often limited by small sample sizes and retrospective designs.
• The lack of specific molecular targets remains a significant challenge in developing effective TNBC treatments.

Conclusions:

• Novel therapeutic strategies targeting TNBC vulnerabilities are actively being explored.
• Future large-scale studies are crucial for defining optimal treatment strategies for TNBC in both advanced and adjuvant settings.
• Identifying new biomarkers and overcoming current research limitations are key priorities for advancing TNBC care.